Search

Your search keyword '"Farge-Bancel, D"' showing total 364 results

Search Constraints

Start Over You searched for: Author "Farge-Bancel, D" Remove constraint Author: "Farge-Bancel, D"
364 results on '"Farge-Bancel, D"'

Search Results

1. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

2. Timing and characteristics of venous thromboembolism after noncancer surgery

3. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study

4. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

5. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

6. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

7. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

8. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism

9. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

10. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site

11. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry

12. DVT Management and Outcome Trends, 2001 to 2014

14. A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis

15. A prognostic score to identify low‐risk outpatients with acute deep vein thrombosis in the upper extremity

16. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism

18. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

20. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

22. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

23. Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors

24. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

25. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

27. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project

28. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

30. Timing and characteristics of venous thromboembolism after noncancer surgery

31. The EBMT activity survey: 1990–2010

35. Predictors of active cancer thromboembolic outcomes

36. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

38. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

39. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

40. Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry

41. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

42. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study

43. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

48. Diagnosis of Lupus, age at HSCT and CD34+ graft selection are the main risk factors for secondary autoimmune diseases occurring after HSCT for autoimmune diseases: a retrospective study of the EBMT Autoimmune Disease Working Party: O428

49. Incidence and risk factors for secondary autoimmune diseases after cord blood transplantation. Retrospective analysis on behalf of Eurocord and the EBMT Working Party Autoimmune Diseases: O179

50. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

Catalog

Books, media, physical & digital resources